Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 647 across all filing types
Latest filing 2026-01-19 Regulatory Filings
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from a South Korean company (GemVax) regarding a 'Correction Report' (정정신고) for a 'Stock Collateral Agreement' (주식 담보제공 계약). This type of filing is a standard disclosure of financial/capital structure changes involving the company's major shareholders and their collateralized shares. It does not fit into specific categories like Earnings Release, Annual Report, or M&A, and is best classified as a general regulatory filing (RNS) within the provided schema.
2026-01-19 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required under the Capital Markets Act in South Korea when a shareholder's stake in a company changes significantly (often referred to as a 5% rule filing). It details the shareholding status, changes in ownership, and contractual relationships (pledges, loans) of the major shareholder (Gem & Company) and its special related parties in GemVax & KAEL. This falls under the 'Major Shareholding Notification' category.
2026-01-16 Korean
[기재정정]주요사항보고서(신주인수권부사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) from GemVax & KAEL, specifically detailing a correction (정정신고) to a previously filed decision to issue bonds with warrants (신주인수권부사채 발행결정). It outlines changes to the total issuance amount, the list of investors, and the use of proceeds. This falls under the category of capital structure changes and financing activities, which is classified as 'Capital/Financing Update' (CAP).
2026-01-15 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Share Issue/Capital Change Classification · 95% confidence The document is a regulatory filing from a South Korean company (GemVax) regarding the 'Execution of a Stock Collateral Agreement involving a change in the largest shareholder'. It details specific collateral contracts, debt amounts, and the terms of the pledge. This type of disclosure is a standard regulatory requirement for listed companies to report changes in share ownership or encumbrances on shares held by major shareholders. It does not fit into specific categories like Earnings Release, Annual Report, or M&A, and is best classified as a Regulatory Filing (RNS) as it is a formal disclosure to the exchange.
2026-01-15 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Share Issue/Capital Change Classification · 95% confidence The document is a regulatory filing from a Korean company (GemVax) regarding a 'Correction Report' (정정신고) for a 'Pledge of Shares' (주식 담보제공 계약). This type of filing is a standard regulatory disclosure in the Korean market (DART system) concerning changes in capital structure and collateralization of shares by the major shareholder. Since it details specific financial arrangements and collateral pledges rather than being a general announcement or a report publication notice, it falls under the 'Regulatory Filings' category as a specific corporate disclosure.
2026-01-12 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is specifically used to report insider transactions, changes in shareholdings by major shareholders, or director dealings. In the provided taxonomy, 'Director's Dealing' (DIRS) is the appropriate category for reports detailing personal share transactions by company directors, executives, or major shareholders.
2026-01-06 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.